This proposal is designed to definitively assess the role of NF-kappaB in cardiac ischemia/reperfusion injury (I/R) and late ischemic preconditioning (IPC). Although NF-kappaB activation is associated with I/R, the role of NF-kappaB in myocardial injury remains controversial. We hypothesize that blockade of NF-kappaB activation in I/R has a protective effect against MI. We will test this hypothesis by blocking NF-kappaB chronically using a dominant negative transgenic approach, and acutely by specifically blocking interaction between NF-kappaB and promoter sequence with a decoy oligodeoxynucleotide (ODN). Cardiac IPC, including early and late IPC, is the phenomenon in which brief repetitive episodes of ischemia induce a protective state against a later more serious ischemic insult. There is evidence that transcriptional regulation is critical for the protection afforded by late IPC. Specifically, NF-kappaB is thought to play a major role as a signaling molecule for the induction of protective genes such as iNOS, COX-2, and aldose reductase. We will employ a multidisciplinary approach to identify the role of NF-kappaB in late IPC.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
1F32HL073614-01
Application #
6649579
Study Section
Special Emphasis Panel (ZRG1-F10 (20))
Program Officer
Commarato, Michael
Project Start
2003-05-09
Project End
2006-05-08
Budget Start
2003-05-09
Budget End
2004-05-08
Support Year
1
Fiscal Year
2003
Total Cost
$51,904
Indirect Cost
Name
University of Cincinnati
Department
Pharmacology
Type
Schools of Medicine
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221